Dr Neil Came is an expert in haematopathology (blood and bone marrow diseases), working in close collaboration with clinical and pathology colleagues to provide a high standard of care in the diagnosis and monitoring of a wide range of haematological cancers, as well as transfusion and coagulation support of all patients at Peter Mac. Dr Came’s research interest is disease response assessment of plasma cell myeloma. He is an active member of Australian, American and European haematology and flow cytometry societies; is currently working with ICCS and ESCCA toward an international consensus method for minimal residual disease assessment of multiple myeloma by flow cytometry; and is on the editorial board of the journal Cytometry Part B, Clinical Cytometry.
Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, Monreal M, de Tute R, Vergilio JA, Rawstron AC, Paiva B. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016 Jan;90(1):31-9
Came N, Nguyen V, Westerman D, Harrison S. Aggressive and extramedullary plasma cell myeloma evade bone marrow flow cytometric minimal residual disease detection. Br J Haematol. 2016 Jun;173(6):947-9
Came N, Westerman D, Juneja S. The denominator variable in the quantitation of MRD in acute myeloid leukemia. Am J Hematol. 2015 Nov;90(11):E213-5
Pasricha SR, Juneja SK, Westerman DA, Came NA. Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenstrom macroglobulinaemia. J Clin Pathol. 2011 Jun;64(6):520-3